[
  {
    "ts": "2025-11-04T21:13:56+00:00",
    "headline": "Vertex Pharma's Mixed Quarter: How Legacy Products Drove Its Beat",
    "summary": "Vertex stock dipped Tuesday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older CF drug.",
    "url": "https://www.investors.com/news/technology/vertex-stock-vertex-pharmaceuticals-earnings-q3-2025/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "abac1ac4-d46e-3d23-bc1c-1f69af27251c",
      "content": {
        "id": "abac1ac4-d46e-3d23-bc1c-1f69af27251c",
        "contentType": "STORY",
        "title": "Vertex Pharma's Mixed Quarter: How Legacy Products Drove Its Beat",
        "description": "",
        "summary": "Vertex stock dipped Tuesday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older CF drug.",
        "pubDate": "2025-11-04T21:13:56Z",
        "displayTime": "2025-11-04T21:13:56Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/abac1ac4-d46e-3d23-bc1c-1f69af27251c/vertex-pharma-s-mixed.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/36341c7359b2a531328260e35b43cafc",
          "originalWidth": 945,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zSGpiPg1dsrluiyobkeufQ--~B/aD01MzM7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/36341c7359b2a531328260e35b43cafc.cf.webp",
              "width": 945,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/M_JzbS1JiTiKtlMSwwGZaA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/36341c7359b2a531328260e35b43cafc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/vertex-stock-vertex-pharmaceuticals-earnings-q3-2025/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRSP"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-04T15:41:00+00:00",
    "headline": "Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint",
    "summary": "VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.",
    "url": "https://finance.yahoo.com/news/vertex-q3-earnings-beat-stock-154100172.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "28ea9a71-5227-3b32-98cd-ffbe126c680a",
      "content": {
        "id": "28ea9a71-5227-3b32-98cd-ffbe126c680a",
        "contentType": "STORY",
        "title": "Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint",
        "description": "",
        "summary": "VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.",
        "pubDate": "2025-11-04T15:41:00Z",
        "displayTime": "2025-11-04T15:41:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-q3-earnings-beat-stock-154100172.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-q3-earnings-beat-stock-154100172.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-04T13:45:44+00:00",
    "headline": "VRTX Q3 Deep Dive: New Product Launches and Pipeline Progress Shape Outlook",
    "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $11.95 billion at the midpoint. Its non-GAAP profit of $4.80 per share was 4.9% above analysts’ consensus estimates.",
    "url": "https://finance.yahoo.com/news/vrtx-q3-deep-dive-product-134544172.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "80fce672-e598-3b6f-afae-1daf67022d42",
      "content": {
        "id": "80fce672-e598-3b6f-afae-1daf67022d42",
        "contentType": "STORY",
        "title": "VRTX Q3 Deep Dive: New Product Launches and Pipeline Progress Shape Outlook",
        "description": "",
        "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $11.95 billion at the midpoint. Its non-GAAP profit of $4.80 per share was 4.9% above analysts’ consensus estimates.",
        "pubDate": "2025-11-04T13:45:44Z",
        "displayTime": "2025-11-04T13:45:44Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "VRTX Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l6Y31wu10RiElUns.3mORA--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Qe_uhCRKlCGgByoENi3GZg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vrtx-q3-deep-dive-product-134544172.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vrtx-q3-deep-dive-product-134544172.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-04T13:00:00+00:00",
    "headline": "Vortex Energy Corp. Announces Submission of Abstract for Presentation at the 2026 Canadian Hydrogen Convention",
    "summary": "University of Alberta-led research highlights emerging hydrogen storage potential at Robinsons River Salt DomeVANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that the University of Alberta has submitted an abstract titled “Structure Assessment of the Robinson River Salt Dome for Hydrogen Storage” to the Canadian Hydrogen Convention committee, in relation to an opportunity to",
    "url": "https://finance.yahoo.com/news/vortex-energy-corp-announces-submission-130000535.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "30d407e3-4dac-3c6f-b09e-fa19ff0fc8b4",
      "content": {
        "id": "30d407e3-4dac-3c6f-b09e-fa19ff0fc8b4",
        "contentType": "STORY",
        "title": "Vortex Energy Corp. Announces Submission of Abstract for Presentation at the 2026 Canadian Hydrogen Convention",
        "description": "",
        "summary": "University of Alberta-led research highlights emerging hydrogen storage potential at Robinsons River Salt DomeVANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that the University of Alberta has submitted an abstract titled “Structure Assessment of the Robinson River Salt Dome for Hydrogen Storage” to the Canadian Hydrogen Convention committee, in relation to an opportunity to",
        "pubDate": "2025-11-04T13:00:00Z",
        "displayTime": "2025-11-04T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/513e0883ed6a478a2036119d3f0619da",
          "originalWidth": 1297,
          "originalHeight": 505,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tk46GwrdVa_eAkyzErR_YA--~B/aD01MDU7dz0xMjk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/513e0883ed6a478a2036119d3f0619da.cf.webp",
              "width": 1297,
              "height": 505,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5H.IMNgt5uPIavdTamohpQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/513e0883ed6a478a2036119d3f0619da.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vortex-energy-corp-announces-submission-130000535.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vortex-energy-corp-announces-submission-130000535.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX.CN"
            },
            {
              "symbol": "VTECF"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-04T11:15:00+00:00",
    "headline": "Vertex’s new pain, blood disorder drugs miss Wall Street expectations",
    "summary": "While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear revenue misses,” wrote a Raymond James analyst.",
    "url": "https://www.biopharmadive.com/news/vertex-earnings-journavx-casgevy-sales-new-products/804581/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "4a1bcbc2-8b50-3d6d-b75a-6f2fd6395c3f",
      "content": {
        "id": "4a1bcbc2-8b50-3d6d-b75a-6f2fd6395c3f",
        "contentType": "STORY",
        "title": "Vertex’s new pain, blood disorder drugs miss Wall Street expectations",
        "description": "",
        "summary": "While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear revenue misses,” wrote a Raymond James analyst.",
        "pubDate": "2025-11-04T11:15:00Z",
        "displayTime": "2025-11-04T11:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/fd80ed88a0ff404b567c29f01609a8e1",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VclBsduXm.HBXQHM.mf4Xg--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/fd80ed88a0ff404b567c29f01609a8e1.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RTPOa7scL4Eve6dLBNR1uQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/fd80ed88a0ff404b567c29f01609a8e1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/vertex-earnings-journavx-casgevy-sales-new-products/804581/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pain-blood-disorder-drugs-111500318.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]